Myriad Genetics, Inc. (MYGN) Monday reported fourth-quarter net loss of $7.9 million or $0.08 per share, compared to $42.5 million or $0.47 per share last year.
Adjusted net income of $3.9 million or $0.04 per share, compared to $3.2 million or $0.03 per share last year.
Revenues were $209.8 million, compared to $210.6 million last year.
Looking forward to full year 2026, the company expects revenues of $860 million to $880 million.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.